These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20521352)

  • 1. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
    Spigel DR; Hainsworth JD; Gandhi JG; Gian VG; Peyton JD; West-Osterfield K; Clark BL; Vazquez ER; Jones SF; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):862-6. PubMed ID: 20521352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
    Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
    Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
    Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
    Bryce AH; Mattar B; Hillman SL; Adjei AA; Kugler JW; Rowland K; Wender DB; Soori G; Perez EA; Jett JR
    Am J Clin Oncol; 2010 Aug; 33(4):353-7. PubMed ID: 19935387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
    Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
    Miller AA; Niell HB
    Lung Cancer; 2001; 33(2-3):241-8. PubMed ID: 11551419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
    Schiller JH; Adak S; Cella D; DeVore RF; Johnson DH
    J Clin Oncol; 2001 Apr; 19(8):2114-22. PubMed ID: 11304763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
    Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
    J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
    Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
    Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Miller AA; Wang XF; Bogart JA; Hodgson LD; Rocha Lima CM; Radford JE; Vokes EE; Green MR;
    J Thorac Oncol; 2007 Jul; 2(7):645-51. PubMed ID: 17607121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.